– Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023 –
– To receive $10 million upfront for the execution of a license agreement for Xork, the Company’s next-generation immunoglobulin G (IgG) protease candidate, to be developed with Astellas Gene Therapies’ AT845, an investigational product for the treatment of Pompe disease –
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.
